Aligos Therapeutics (ALGS) Stock
Clinical stage biotech developing liver and viral treatments. Here's the price, business snapshot, and what's worth knowing about Aligos Therapeutics in October 2026.
Aligos Therapeutics (ALGS) is a clinical-stage biotechnology company developing therapies focused on liver and viral diseases, notably programmes addressing chronic hepatitis B and related conditions. As a small-cap, research-led company (market cap around $64.5m), its value is driven largely by clinical trial progress, regulatory milestones and potential partnerships or licensing deals rather than current revenue. Investors should expect high volatility and binary outcomes: positive clinical data or approvals can materially re-rate the stock, while setbacks can lead to sharp declines. Common risks include lengthy development timelines, regulatory uncertainty and the potential need to raise capital, which can dilute shareholders. For those tracking ALGS, keep an eye on trial readouts, pipeline updates, cash runway and collaboration announcements. This information is general and educational, not personalised investment advice — potential investors should consider their risk tolerance and seek independent financial advice where appropriate.
Aligos Therapeutics (ALGS) Stock Forecast
Analyst price target, next 12 months
$74.33
+1241.8% vs today's $5.54
Price range over the last 12 months
Close to its 12-month low
Analysts covering Aligos Therapeutics have a consensus 12-month target of $74.33, above the current price of $5.54.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Aligos Therapeutics stock due to significant potential for growth.
Financial Health
Aligos Therapeutics is generating modest revenue and cash flow, with a stable book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical-stage drug programmes
Pipeline progress and trial readouts drive value, so milestones can create strong share movements — though outcomes can be binary and unpredictable.
Upcoming catalysts and milestones
Regulatory decisions, trial data and partnership news are likely catalysts to watch; these events can lead to rapid gains or losses.
Cash position and dilution
As a small-cap biotech, monitoring cash runway and fundraising plans is important because additional capital raises can dilute shareholders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
